Enfortumab

Brand names: Padcev · Active ingredient: Enfortumab Vedotin

In short: PADCEV®, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). PADCEV®, in combination with p

Forms & strengthsFor Injection: 20 mg and 30 mg of enfortumab vedotin-ejfv as a white to off-white lyophilized powder in a single-dose vial for reconstitution.
LabelSeagen Inc.
Label updatedAug 17, 2026

What is Enfortumab used for?

PADCEV®, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).

PADCEV®, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC).

PADCEV, as a single agent, is indicated for the treatment of adult patients with la/mUC who:

•have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or

•are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

⚠ Boxed warning (FDA's strongest warning)

•

PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.

•

Closely monitor patients for skin reactions.

•

Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.

•

Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].

Enfortumab dosage

The recommended dosages for PADCEV in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, and PADCEV as a single agent are presented in Table 1 and Table 2.

Administer PADCEV as an intravenous infusion over 30 minutes as recommended . Administer PADCEV prior to pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph if administering on the same day.

Indication | Recommended PADCEV Dosage | Duration of Therapy

Neoadjuvant and Adjuvant Muscle Invasive Bladder Cancer (MIBC) | PADCEV 1.25 mg/kg (up to a maximum of 125 mg for patients ≥100 kg) on Days 1 and 8 of a 21-day cycle. | Patients who are cisplatin-eligible

Cisplatin ineligibility is defined as meeting at least one of the following criteria: Creatinine clearance of less than 60 mL/min, ECOG PS 2 or higher, Grade 2 or higher hearing loss, NYHA Class III or higher heart failure, or Grade 2 or higher peripheral neuropathy.

:

•

Neoadjuvant: 4 cycles or until disease progression that precludes curative intent cystectomy or unacceptable toxicity.

•

Adjuvant: 5 cycles or until disease recurrence or unacceptable toxicity.

Patients who are cisplatin-ineligible

:

•

Neoadjuvant: 3 cycles or until disease progression that precludes curative intent cystectomy or unacceptable toxicity.

•

Adjuvant: 6 cycles or until disease recurrence or unacceptable toxicity.

Locally advanced or metastatic Urothelial Cancer (la/mUC) | PADCEV 1.25 mg/kg (up to a maximum of 125 mg for patients ≥100 kg) on Days 1 and 8 of a 21-day cycle. | Until disease progression or unacceptable toxicity.

Indication | Recommended PADCEV Dosage | Duration of Therapy

Locally advanced or metastatic Urothelial Cancer (la/mUC) | PADCEV 1.25 mg/kg (up to a maximum of 125 mg for patients ≥100 kg) on Days 1, 8, and 15 of a 28-day cycle. | Until disease progression or unacceptable toxicity.

Adverse Reaction | Severity

Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening. | Dose Modification

Skin Reactions

| For persistent or recurrent Grade 2 skin reactions | Consider withholding until Grade ≤1, then resume treatment at the same dose level or dose reduce by one dose level.

Grade 3 skin reactions | Withhold until Grade ≤1, then resume treatment at the same dose level or dose reduce by one dose level.

Suspected SJS or TEN | Immediately withhold, consult a specialist to confirm the diagnosis. If not SJS/TEN, see Grade 2-4 skin reactions.

Confirmed SJS or TEN; Grade 4 or recurrent Grade 3 skin reactions | Permanently discontinue.

Hyperglycemia

| Blood glucose >250 mg/dL | Withhold until elevated blood glucose has improved to ≤250 mg/dL, then resume treatment at the same dose level. …

How to take Enfortumab — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Skin Reactions

Inform patients that severe skin reactions including SJS and TEN with fatal outcomes have occurred after administration of PADCEV, predominantly during the first cycle of treatment but may occur later.

Advise patients to contact their healthcare provider immediately if they develop new target lesions, progressively worsening skin reactions, severe blistering, or peeling of the skin .

Hyperglycemia

Inform patients about the risk of hyperglycemia and how to recognize associated symptoms .

Pneumonitis/ILD

Advise patients to immediately report new or worsening respiratory symptoms .

Peripheral Neuropathy

Inform patients to report to their healthcare provider any numbness and tingling of the hands or feet or muscle weakness .

Ocular disorders

Advise patients to contact their healthcare provider if they experience any visual changes . In order to prevent or treat dry eyes, advise patients to use artificial tear substitutes.

Infusion Site Extravasation

Inform patients that infusion site reactions have occurred after administration of PADCEV. …

Warnings & precautions

Do not take this medicine if: None.

Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV. SJS and TEN occurred predominantly during the first cycle of treatment but may occur later.

Skin reactions occurred in 65% (all grades) of the 570 patients treated with PADCEV in combination with intravenous pembrolizumab for the treatment of MIBC in clinical trials. The majority of the skin reactions that occurred with combination therapy included rash and maculo-papular rash. Grade 3-4 skin reactions occurred in 13% of patients (Grade 3: 12%, Grade 4: 1.1%), including maculo-papular rash, rash, Stevens-Johnson syndrome, dermatitis, exfoliative generalized dermatitis, toxic skin eruption, acute generalized exanthematous pustulosis, bullous dermatitis, erythema, macular rash, and pruritic rash. A fatal reaction of TEN occurred in one patient (0.2%). The median time to onset of severe skin reactions was 0.6 months (range: 0.1 to 24 months). Skin reactions led to discontinuation of PADCEV in 8% of patients . Of the patients who experienced a skin reaction and had data regarding resolution (n=367), 87% had complete resolution and 13% had residual skin reactions at their last evaluation. Of the patients with residual skin reactions at last evaluation, 31% (15/49) had Grade ≥2 skin reactions.

Skin reactions occurred in 70% (all grades) of the 564 patients treated with PADCEV in combination with intravenous pembrolizumab for the treatment of la/mUC in clinical trials. When PADCEV was given in combination with intravenous pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate compared to PADCEV as a single agent. The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash, and papular rash. …

Enfortumab side effects

The following serious adverse reactions are described elsewhere in the labeling:

•Skin Reactions

•Hyperglycemia

•Pneumonitis/Interstitial Lung Disease (ILD)

•Peripheral Neuropathy

•Ocular Disorders

•Infusion Site Extravasation

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to PADCEV 1.25 mg/kg in combination with intravenous pembrolizumab for the treatment of MIBC in 570 patients in EV-303 (NCT03924895) and EV-304 (NCT04700124) and for the treatment of la/mUC in 564 patients in EV-302 (NCT04223856) and EV-103 (NCT03288545); PADCEV as a single agent at 1.25 mg/kg in 720 patients in EV-301 (NCT03474107), EV‑201 (NCT03219333), EV-203 (NCT04995419), EV-101 (NCT02091999), and EV-102 (NCT03070990). Ocular disorders reflect 384 patients in EV‑201, EV-101, and EV-102. …

Drug interactions

Dual P-gp and Strong CYP3A4 Inhibitors

Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure , which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.

About this medicine

Enfortumab vedotin-ejfv is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD-1006). Conjugation takes place on cysteine residues that comprise the interchain disulfide bonds of the antibody to yield a product with a drug-to-antibody ratio of approximately 3.8:1. The molecular weight is approximately 152 kDa.

Figure 1. Structural Formula

Approximately 4 molecules of MMAE are attached to each antibody molecule. Enfortumab vedotin-ejfv is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells and the small molecule components are produced by chemical synthesis.

PADCEV (enfortumab vedotin-ejfv) for injection is provided as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials for intravenous use. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b5631d3e-4604-4363-8f20-11dfc5a4a8ed. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate